2025
Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV.
Corti F, Locri F, Plastino F, Perrotta P, Zsebo K, Ristori E, Yin X, Song E, André H, Simons M. Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV. Translational Vision Science & Technology 2025, 14: 10. PMID: 39792057, PMCID: PMC11730891, DOI: 10.1167/tvst.14.1.10.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationLaser-induced choroidal neovascularizationAnti-VEGF therapyTransendothelial electrical resistanceVEGF-A activityChoroidal neovascularizationIntravitreal injectionRetinal lesionsLong-term anti-VEGF therapyMurine laser-induced choroidal neovascularizationNeovascular age-related macular degenerationWet age-related macular degenerationAlteration of visual acuityIntravitreal anti-VEGF therapySide effectsLocal intravitreal injectionReduced edema formationSuppression of edemaRelated side effectsPermeability in vitroEndothelial cell junctionsNeovascular AMDVisual acuityAssessed in vitroMacular degeneration
2024
Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies A World Health Organization Pharmacovigilance Study
Yang J, Jung S, Kim M, Lee S, Yon D, Shin J, Lee J. Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies A World Health Organization Pharmacovigilance Study. Ophthalmology 2024, 132: 62-78. PMID: 39004231, DOI: 10.1016/j.ophtha.2024.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabCardiovascular DiseasesCerebrovascular DisordersDatabases, FactualFemaleHumansIntravitreal InjectionsMaleMiddle AgedOdds RatioPharmacovigilanceRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AWorld Health OrganizationConceptsIntravitreal anti-VEGF treatmentAdverse drug reactionsAnti-VEGF treatmentAnti-VEGFAtrial fibrillationIntravitreal anti-VEGF therapyCerebral hemorrhageIndividual case safety reportsInter-drugReports of myocardial infarctionMyocardial infarctionDisproportionate Bayesian reportingIntravitreal anti-VEGFAnti-VEGF therapyCarotid artery stenosisIncreasing reportsHypertensive crisisCase-noncase studySupraventricular tachycardiaAtrial flutterSubarachnoid hemorrhageIntravitrealArtery stenosisAngina pectorisOdds ratioMolecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).
Zaemes J, Hugaboom M, Shah V, Haas N, McDermott D, Jegede O, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Hurwitz M, Wu C, Einstein D, Hammers H, Signoretti S, West D, Denize T, Atkins M, Braun D. Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC). Journal Of Clinical Oncology 2024, 42: 4546-4546. DOI: 10.1200/jco.2024.42.16_suppl.4546.Peer-Reviewed Original ResearchObjective response rateImmune checkpoint blockadeProgression-free survivalProgressive diseaseAnti-VEGFOverall survivalAssociated with higher progression-free survivalTumor samplesAdvanced clear cell renal cell carcinomaCombined immune checkpoint blockadeHigher progression-free survivalIncreased PFSImmune checkpoint blockade therapyShorter progression-free survivalClear cell renal cell carcinomaAnti-VEGF therapyCell renal cell carcinomaWeeks of therapyRenal cell carcinomaBiomarkers of efficacyFFPE tumor samplesNIVO monotherapyCheckpoint blockadeDecreased OSProspective trials
2020
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
Chong W, Lim C, Sinha A, Tan C, Chan G, Huang Y, Kumarakulasinghe N, Sundar R, Jeyasekharan A, Loh W, Tay J, Yadav K, Wang L, Wong A, Kong L, Soo R, Lau J, Soon Y, Goh R, Ho F, Chong S, Lee S, Loh K, Tai B, Lim Y, Goh B. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research 2020, 26: 5320-5328. PMID: 32816944, DOI: 10.1158/1078-0432.ccr-20-1727.Peer-Reviewed Original ResearchConceptsLocally advanced nasopharyngeal carcinomaAdvanced nasopharyngeal carcinomaNasopharyngeal carcinomaConcurrent chemoradiationGemcitabine chemotherapyArm CIncreased immune cell infiltrationComplete metabolic responsePosttreatment tumor biopsiesAnti-VEGF therapyArm A patientsRelapse-free survivalMetastatic nasopharyngeal carcinomaImmune cell infiltrationImmune cell traffickingVEGF axisTumor responseInduction cisplatinAntiangiogenic therapyTumor biopsiesTumor perfusionA patientsFDG-PETPericyte coverageStandard treatment
2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Science Translational Medicine 2018, 10 PMID: 29540614, PMCID: PMC5936748, DOI: 10.1126/scitranslmed.aag0945.Peer-Reviewed Original ResearchConceptsVEGF therapyInterleukin-6Breast cancerMouse modelAnti-vascular endothelial growth factor therapyEndothelial growth factor therapyTumor vasculatureAnti-VEGF therapyAnti-VEGF treatmentIL-6 blockadeGrowth factor therapyIL-6 productionFGF-2Up-regulates IL-6Second mouse modelFGF-2 expressionTumor cell proliferationFactor therapyGrowth factor 2Proinflammatory factorsMetastatic sitesBC patientsObese miceReceptor inhibitionSystemic concentrations
2017
Age‐related macular degeneration: using morphological predictors to modify current treatment protocols
Ashraf M, Souka A, Adelman RA. Age‐related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmologica 2017, 96: 120-133. PMID: 29130626, DOI: 10.1111/aos.13565.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationPigment epithelial detachmentChoroidal neovascular membranePosterior vitreous detachmentNeovascular age-related macular degenerationRetinal angiomatous proliferationSubretinal fluidIntraretinal cystsVitreomacular adhesionVisual outcomeVisual acuityPrognostic indicatorMacular degenerationAnti-vascular endothelial growth factorLarger choroidal neovascular membranesWet age-related macular degenerationOlder ageCNV sizeFinal visual outcomeGood visual outcomeAnti-VEGF therapyPoor prognostic indicatorCurrent treatment protocolsEndothelial growth factorInjection frequency
2016
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2014
Current Perspectives in the Management of Retinopathy of Prematurity
Dogra M, Katoch D. Current Perspectives in the Management of Retinopathy of Prematurity. Delhi Journal Of Ophthalmology 2014, 25: 108-117. DOI: 10.7869/djo.90.Peer-Reviewed Original ResearchNational Neonatology ForumLaser photocoagulationPremature babiesManagement of retinopathy of prematurityConfluent laser treatmentLens sparing vitrectomyPrevention of ROPTreatment of ROPAnti-VEGF therapyDiode laser photocoagulationRetinopathy of prematurityHigh birth weightStandard of careTreatable ROPSevere ROPAnti-VEGFMature babiesRescue therapyNational Neonatology Forum of IndiaChildhood blindnessBirth weightOxygen saturation levelsScreening programLaser treatmentPhotocoagulation
2011
P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial.
Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schöffski P, Awada A, Yasenchak C, Burris H, Ramies D, Shen X, Winer E. P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial. Cancer Research 2011, 71: p1-17-10-p1-17-10. DOI: 10.1158/0008-5472.sabcs11-p1-17-10.Peer-Reviewed Original ResearchMetastatic breast cancerObjective response rateStable diseasePartial responseBone scanBreast cancerBone metastasesNarcotic useDiscontinuation trialClinical activityWk 12Common related adverse eventsOverall disease control ratePost-baseline tumour assessmentPrior anti-VEGF therapyBone marker analysesFatigue/astheniaPrior treatment regimensPrior treatment statusDisease control rateHand-foot syndromeProgression-free survivalRelated adverse eventsAnti-VEGF therapyInvasive ductal carcinoma
2008
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy. Clinical Cancer Research 2008, 14: 7871-7877. PMID: 19047116, DOI: 10.1158/1078-0432.ccr-08-0593.Peer-Reviewed Original ResearchConceptsAdvanced breast cancer patientsRefractory breast cancerBreast cancer patientsBreast cancerPlasma VEGFCancer patientsTreatment outcomesSide effectsAnti-vascular endothelial growth factor therapyAdequate end-organ functionEndothelial growth factor therapyImportant new treatment modalityTumor hormone receptor statusMonoclonal anti-VEGF antibodyPrior chemotherapy regimensEnd-organ functionHormone receptor statusAnti-VEGF therapyMetastatic breast cancerGrowth factor therapyNew treatment modalitiesWarrants further evaluationAnti-VEGF antibodyBaseline VEGFEligible patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply